TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $127.33.

Several equities research analysts recently commented on TMDX shares. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Tuesday. Oppenheimer raised their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler restated an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th.

TransMedics Group Trading Down 0.3%

NASDAQ:TMDX traded down $0.38 on Tuesday, reaching $123.62. 864,452 shares of the stock traded hands, compared to its average volume of 1,364,561. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The company's 50 day moving average is $113.37 and its 200-day moving average is $83.69. The firm has a market capitalization of $4.18 billion, a price-to-earnings ratio of 90.77 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period in the prior year, the firm posted $0.35 EPS. The company's quarterly revenue was up 48.2% on a year-over-year basis. Equities research analysts anticipate that TransMedics Group will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider now directly owns 13,955 shares of the company's stock, valued at $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the transaction, the director now directly owns 2,866 shares in the company, valued at $362,405.70. The trade was a 63.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,418 shares of company stock valued at $1,512,613. Corporate insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after acquiring an additional 2,209,996 shares during the period. Braidwell LP purchased a new stake in shares of TransMedics Group during the 4th quarter valued at $57,493,000. Norges Bank bought a new stake in shares of TransMedics Group during the 4th quarter worth $22,861,000. Mackenzie Financial Corp raised its stake in shares of TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after purchasing an additional 349,403 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.